Strata Critical Medical (SRTA) Current Deferred Revenue (2019 - 2025)

Strata Critical Medical has disclosed Current Deferred Revenue across 7 years of filings, most recently posting $9.1 million for Q2 2025.

• In Q2 2025, Current Deferred Revenue fell 1.66% year-over-year to $9.1 million; the TTM figure through Jun 2025 stood at $9.1 million (down 1.66% YoY), while the FY2024 annual figure was $6.7 million, down 2.76% from the prior year.
• Current Deferred Revenue rose to $9.1 million in Q2 2025, from $8.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for SRTA reached as high as $10.0 million in Q2 2023 and fell as low as $4.4 million in Q1 2021.
• The 5-year median for Current Deferred Revenue is $6.8 million (2022), against an average of $7.1 million.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 61.41% — and 2024, when it decreased 7.47%.
• A 5-year view of Current Deferred Revenue shows it stood at $6.0 million in 2021, then climbed by 12.27% to $6.7 million in 2022, then rose by 2.03% to $6.8 million in 2023, then fell by 2.76% to $6.7 million in 2024, then surged by 36.9% to $9.1 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $9.1 million, $8.0 million, and $6.7 million for Q2 2025, Q1 2025, and Q4 2024 respectively.